Relafen 750, a advanced compound of naproxen, represents a compelling example from the biochemical pharmacy standpoint. This mode of action, mainly involving blocking of cyclooxygenase enzymes and COX-1 and COX-2 – results to the decrease in prostaglandin creation. Within the biochemical context, the drug's effectiveness is strongly linked to the